Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
The FEBS Journal
|
December 16, 2018
The structure of mammalian β-mannosidase provides insight into β-mannosidosis and nystagmus
Heidi Gytz, Jason Liang, Yingke Liang, et al.
Frontiers in Immunology
|
August 28, 2020
Functional and Structural Characterization of a Potent C1q Inhibitor Targeting the Classical Pathway of the Complement System
Nick S Laursen, Dennis V Pedersen, Heidi Gytz, et al.
The CRISPR Journal
|
April 26, 2019
Double-Stranded Biotinylated Donor Enhances Homology-Directed Repair in Combination with Cas9 Monoavidin in Mammalian Cells
Philip J R Roche, Heidi Gytz, Faiz Hussain, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 23, 2023
Bispecific Complement Engagers for Targeted Complement Activation
Dennis V Pedersen, Heidi Gytz, Mikael B L Winkler, et al.
Nucleic Acids Research
|
November 19, 2015
Structural basis for RNA-genome recognition during bacteriophage Qβ replication
Heidi Gytz, Durita Mohr, Paulina Seweryn, et al.
EMBO Molecular Medicine
|
February 17, 2023
Nanobody-mediated complement activation to kill HIV-infected cells
Maria Lange Pedersen, Dennis Vestergaard Pedersen, Mikael Becher Lykkegaard Winkler, et al.
Mabs
|
May 4, 2026
Structure-function analysis of empasiprubart, a calcium- and pH-dependent clinical phase complement C2 blocking antibody
Laura Bracke, Heidi Gytz Olesen, Erwin Pannecoucke, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 10, 2020
An Ultrahigh-Affinity Complement C4b-Specific Nanobody Inhibits In Vivo Assembly of the Classical Pathway Proconvertase
Alessandra Zarantonello, Jessy Presumey, Léa Simoni, et al.
Biology of the Cell
|
September 28, 2016
Apoptotic properties of the type 1 interferon induced family of human mitochondrial membrane ISG12 proteins
Heidi Gytz, Mariann F Hansen, Signe Skovbjerg, et al.
Nature Communications
|
August 16, 2025
Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart
Inge Van de Walle, Laura Bracke, Heidi Gytz Olesen, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
The FEBS Journal
|
December 16, 2018
The structure of mammalian β-mannosidase provides insight into β-mannosidosis and nystagmus
Heidi Gytz, Jason Liang, Yingke Liang, et al.
Frontiers in Immunology
|
August 28, 2020
Functional and Structural Characterization of a Potent C1q Inhibitor Targeting the Classical Pathway of the Complement System
Nick S Laursen, Dennis V Pedersen, Heidi Gytz, et al.
The CRISPR Journal
|
April 26, 2019
Double-Stranded Biotinylated Donor Enhances Homology-Directed Repair in Combination with Cas9 Monoavidin in Mammalian Cells
Philip J R Roche, Heidi Gytz, Faiz Hussain, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 23, 2023
Bispecific Complement Engagers for Targeted Complement Activation
Dennis V Pedersen, Heidi Gytz, Mikael B L Winkler, et al.
Nucleic Acids Research
|
November 19, 2015
Structural basis for RNA-genome recognition during bacteriophage Qβ replication
Heidi Gytz, Durita Mohr, Paulina Seweryn, et al.
EMBO Molecular Medicine
|
February 17, 2023
Nanobody-mediated complement activation to kill HIV-infected cells
Maria Lange Pedersen, Dennis Vestergaard Pedersen, Mikael Becher Lykkegaard Winkler, et al.
Mabs
|
May 4, 2026
Structure-function analysis of empasiprubart, a calcium- and pH-dependent clinical phase complement C2 blocking antibody
Laura Bracke, Heidi Gytz Olesen, Erwin Pannecoucke, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 10, 2020
An Ultrahigh-Affinity Complement C4b-Specific Nanobody Inhibits In Vivo Assembly of the Classical Pathway Proconvertase
Alessandra Zarantonello, Jessy Presumey, Léa Simoni, et al.
Biology of the Cell
|
September 28, 2016
Apoptotic properties of the type 1 interferon induced family of human mitochondrial membrane ISG12 proteins
Heidi Gytz, Mariann F Hansen, Signe Skovbjerg, et al.
Nature Communications
|
August 16, 2025
Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart
Inge Van de Walle, Laura Bracke, Heidi Gytz Olesen, et al.
Page
of 2